Tenofovir use and urinary biomarkers among HIV-infected women in the women's interagency HIV study (WIHS)

Journal of Acquired Immune Deficiency Syndromes

Volumn 62, Issue 4, 2013, Pages 388-395

  Oboho, Ikwo ^a   Abraham, Alison G ^b   Benning, Lorie ^b   Anastos, Kathryn ^c   Sharma, Anjali ^d   Young, Mary ^e   Burian, Pamela ^f   Gandhi, Monica ^g   Cohen, Mardge ^h   Szczech, Lynda ⁱ  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c MONTEFIORE MEDICAL CENTER   (United States)

^d SUNY DOWNSTATE MEDICAL CENTER   (United States)

^e GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^f UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h Jr Hospital of Cook County   (United States)

ⁱ Pharmaceutical Product Development   (United States)

Author keywords

HIV infected women; Tenofovir; Urinary biomarkers

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR; BETA 2 MICROGLOBULIN; BIOLOGICAL MARKER; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; N ACETYL BETA GLUCOSAMINIDASE; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; STAVUDINE; TENOFOVIR DISOPROXIL; VIRUS RNA;

ADULT; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIAGNOSTIC TEST ACCURACY STUDY; DRUG EFFICACY; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLOMERULUS FILTRATION RATE; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MEDICAL HISTORY; MULTICENTER STUDY; PRIORITY JOURNAL; PROPENSITY SCORE; PROTEIN URINE LEVEL; PROTEINURIA; RISK FACTOR; SENSITIVITY AND SPECIFICITY; TUBULAR DYSFUNCTION; URINALYSIS;

EID: 85027931127     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31828175c9     Document Type: Article

References (31)

1. Antoniou T, Raboud J, Chirhin S, et al. Incidence of and risk factors for tenofovir-induced nephrotoxicity: a retrospective cohort study. HIV Med. 2005;6:284-290.
2. Barrios A, Garcia-Benayas T, Gonzalez-Lahoz J, et al. Tenofovir-related nephrotoxicity in HIV-infected patients. AIDS. 2004;18:960-963.
3. Karras A, Lafaurie M, Furco A, et al. Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clin Infect Dis. 2003;36:1070-1073.
4. Coresh J, Astor BC, Greene T, et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis. 2003;41: 1-12.
5. Lew SW, Bosch JP. Effect of diet on creatinine clearance and excretion in young and elderly healthy subjects and in patients with renal disease. J Am Soc Nephrol. 1991;2:856-865.
6. Mishra J, Ma Q, Prada A, et al. Identification of neutrophil gelatinaseassociated lipocalin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol. 2003;14:2534-2543.
7. Price RG. The role of NAG (N-acetyl-beta-D-glucosaminidase) in the diagnosis of kidney disease including the monitoring of nephrotoxicity. Clin Nephrol. 1992;38(suppl 1):S14-S19.
8. Thielemans N, Lauwerys R, Bernard A. Competition between albumin and low-molecular-weight proteins for renal tubular uptake in experimental nephropathies. Nephron. 1994;66:453-458.
9. Nickolas TL, O'Rouke MJ, Yang J, et al. Sensitivity and specificity of a single emergency department measurement of urinary neutrophil gelatinase- associated lipocalin for diagnosing acute kidney injury. Ann Intern Med. 2008;148:810-819.
10. Doi K, Negishi K, Ishizu T, et al. Evaluation of new acute kidney injury biomarkers in a mixed intensive care unit. Crit Care Med. 2011;39: 2464-2469.
11. Nauta FL, Boertien WE, Bakker SJ, et al. Glomerular and tubular damage markers are elevated in patients with diabetes. Diabetes Care. 2011; 34:975-981.
12. Barkan SE, Melnick SL, Preston-Martin S, et al. The Women's Interagency HIV Study. WIHS Collaborative Study Group. Epidemiology. 1998;9:117-125.
13. Bacon MC, Von Wyl W, Alden C, et al. The Women's Interagency HIV Study: an observational cohort brings clinical sciences to the bench. Clin Diagn Lab Immunol. 2005;12:1013-1019.
14. Rosenbaum PR, Rubin D. Constructing a control group using multivariate matched sampling methods that incorporate the propensity score. Am Stat. 1985;39:33-38.
15. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604-612.
16. Gatanaga H, Tachikawa N, Nikuchi Y, et al. Urinary beta2-microglobulin as a possible sensitive marker for renal injury caused by tenofovir disoproxil fumarate. AIDS Res Hum Retroviruses. 2006;22:744-748.
17. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics. 1986;42:121-130.
18. Nelson M, Azwa A, Sokwala A, et al. Fanconi syndrome and lactic acidosis associated with stavudine and lamivudine therapy. AIDS. 2008;22:1374-1376.
19. Dauchy FA, Lawson-Ayayi S, de La Faille R, et al. Increased risk of abnormal proximal renal tubular function with HIV infection and antiretroviral therapy. Kidney Int. 2011;80:302-309.
20. Gallant JE, Parish MA, Keruly JC, et al. Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. Clin Infect Dis. 2005;40:1194-1198.
21. Kinai E, Hanabusa H. Progressive renal tubular dysfunction associated with long-term use of tenofovir DF. AIDS Res Hum Retroviruses. 2009; 25:387-394.
22. El-SadrWM, Lundgren JD, Neaton JD, et al. Strategies for Management of Antiretroviral Therapy (SMART) Study Group. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355:2283-2296.
23. Overton ET, Patel P, Mondy K, et al. Cystatin C and baseline renal function among HIV-infected persons in the SUN Study. AIDS Res Hum Retroviruses. 2012;28:148-155.
24. Post FA, Moyle GJ, Stellbrink HJ, et al. Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviralnaive, HIV-1-infected adults: 48-week results from the ASSERT study. J Acquir Immune Defic Syndr. 2010;55:49-57.
25. Goicoechea M, Liu S, Best B, et al. Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy. J Infect Dis. 2008;197: 102-108.
26. Nishijima T, Gatanaga H, Komatsu H, et al. Renal function declines more in tenofovir- than abacavir-based antiretroviral therapy in low-body weight treatment-naïve patients with HIV infection. PLoS One. 2012;7:e29977.
27. Chaumont A, De Winter F, Dumont X, et al. The threshold level of urinary cadmium associated with increased urinary excretion of retinolbinding protein and beta 2-microglobulin: a re-assessment in a large cohort of nickel-cadmium battery workers. Occup Environ Med. 2011; 68:257-264.
28. Thrailkill KM, Moreau CS, Cockrell GE, et al. Disease and genderspecific dysregulation of NGAL and MMP-9 in type 1 diabetes mellitus. Endocrine. 2010;37:336-343.
29. Seth P, Porter D, Lahti-Domenici J, et al. Cellular and molecular targets of estrogen in normal human breast tissue. Cancer Res. 2002; 62:4540-4544.
30. Gan SL, Chia SE, Chio LF, et al. Urinary beta 2- and alpha1-microglobulin levels in normal subjects in Singapore. Occup Med. 1994;44:195-200.
31. Agirbasli M, Radhakrishnamurthy B, Jiang X, et al. Urinary N-acetylbeta- D-glucosaminidase changes in relation to age, sex, race, and diastolic and systolic blood pressure in a young adult biracial population. The Bogalusa Heart Study. Am J Hypertens. 1996;9:157-161.